For research and educational purposes only. Not medical advice.
Ipamorelin Reference
Educational, not medical advice reference for Ipamorelin: GH Release, Sleep; regulatory status, evidence posture, source review, and schedule no…
Reference summary
Early human PK/PD work in healthy volunteers confirmed GH release across dose levels, while older preclinical pharmacology emphasized relative selectivity versus older GHRPs. Long-term clinical outcome data remain limited.
Regulatory and posture
- Categories
- GH Release, Sleep
- Aliases
- Ipamorelin acetate, NNC 26-0161
- Evidence posture
- human - Small short-term endocrine studies only. Long-term outcome data are limited.
- Regulatory status
- No FDA-approved ipamorelin drug label. FDA lists ipamorelin acetate among bulk substances with safety-risk concerns for compounding.
- Content review status
- research reference
Selected public sources
- FDA bulk drug substances with significant safety risks
- PubMed: ipamorelin human PK/PD trial
- PubMed: ipamorelin preclinical pharmacology
Related tools
- Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
- BAC water calculator - Solve BAC water volume for a target concentration.
- Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
- Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
- Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
- Injection-site rotation overview - Public overview of the Pro site-rotation planner.